ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Basal release of 6-cyanodopamine from rabbit isolated aorta and its modulation of vascular reactivity.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
6-Cyanodopamine (6-CYD) is a recently identified endogenous catecholamine that exerts positive chronotropic and inotropic actions, but its occurrence in vascular tissue and effects on vascular reactivity are unknown. In endothelium-intact and endothelium-denuded rabbit isolated aortic rings, we investigated the basal release of 6-CYD and its effects on aortic smooth muscle reactivity. 6-Cyanodopamine release was quantified by LC-MS/MS. Isometric tension was recorded to assess concentration-response curves to noradrenaline, adrenaline, and dopamine in aortic rings pre-incubated or not with 6-CYD, whereas vasorelaxation was evaluated in endothelin-1 (ET-1)-pre-contracted rings. Rabbit aorta released significant amounts of 6-CYD, which were largely reduced either by endothelium removal or pre-incubation with the NOX1/4 inhibitor GKT137831 (1 µM), whereas the nitric oxide (NO) synthase inhibitor L-NAME (100 µM) and the voltage-gated sodium channel blocker tetrodotoxin (TTX, 1 µM) had no significant effect. Addition of 6-CYD (0.1 pM to 10 nM) had no contractile activity itself, but it significantly potentiated noradrenaline- and adrenaline-induced aortic contractions, an effect largely reduced by endothelium removal. The dopamine-induced aortic contractions remained unaffected by 6-CYD. In ET-1-pre-contracted rings, 6-CYD (1 nM-10 µM) produced concentration-dependent relaxations that were significantly reduced by endothelium removal and L-NAME (100 µM), as well as by the soluble guanylyl cyclase (sGC) inhibitors ODQ (100 µM) and methylene blue (10 µM). In conclusion, these findings identify vascular endothelium as a source of 6-CYD and indicate this catecholamine as a novel endogenous modulator of vascular tone, acting through a dual mechanism, namely, potentiating vasoconstriction and producing NO/sGC-dependent vasorelaxation.
Indexed as
Identifiers
42217040What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.